Infervision vs Viz.ai
A 2025 meta-analysis in Translational Stroke Research pooled 12 studies and 15,595 patients on Viz.ai and found shorter door-to-groin times (SMD -0.47) and door-in-door-out times (SMD -0.49), with no significant difference in clinical outcomes. The vendor describes alerts through a mobile app and group messaging with transfer coordination. Its Trust Center lists SOC 2 Type II and ISO 27001, and its ContaCT De Novo (DEN170073, granted February 13, 2018) covers LVO triage on CTA.
For head CT bleeds, Viz ICH has a 2024 Cureus retrospective accuracy study, and Viz ICH+ is part of K232363 of February 5, 2024. Infervision's InferRead CT Stroke.AI holds the triage clearance K211179, which the vendor describes as hemorrhage triage.
Viz.ai is the stronger pick when the hospital also moves LVO patients between sites, since the workflow data and transfer tools sit on that job. Infervision suits a hospital that wants lung nodule reading kept on its own servers, with on-premise or cloud deployment and PACS and RIS friendly tools per the vendor.
Radiology · Reviewed November 2, 2026
Infervision
by Infervision · founded 2016
AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.
Viz.ai
by Viz.ai · founded 2016
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
When to pick each one
Infervision
- Lung nodule CT cleared as K192880
- On-premise or cloud, PACS and RIS friendly
Viz.ai
- Stroke alerts on a mobile app with transfer coordination
- SOC 2 Type II and ISO 27001 on its Trust Center
- ContaCT De Novo for LVO triage, DEN170073
Score
Each row shows points earned of points available under the published rubric.
Infervision
57of 100
Viz.ai
89of 100
| Dimension | Infervision | Viz.ai | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 10 / 10 | -10 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 18.2 / 18.2 | -5.5 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 12 / 12 | -3.6 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Infervision
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Viz.ai
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Sold to health systems after a demo request. |
Evidence
Infervision
FDA decisions
K260973 (opens in new tab)510(k)2026-07-07
InferOperate Suite
K252261 (opens in new tab)510(k)2026-03-13
InferCare RECIST
K250237 (opens in new tab)510(k)2025-09-15
InferOperate Suite
K240554 (opens in new tab)510(k)2025-05-16
InferRead Lung CT.AI
K211179 (opens in new tab)510(k)2021-08-12
InferRead CT Stroke.AI
Show 1 more
K192880 (opens in new tab)510(k)2020-07-02
InferRead Lung CT.AI
Peer-reviewed
4 PubMed records name Infervision.
- Spatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy. (opens in new tab)
- AI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation. (opens in new tab)
- Impact of dose reduction and iterative reconstruction algorithm on the detectability of pulmonary nodules by artificial intelligence. (opens in new tab)
Viz.ai
FDA decisions
K250354 (opens in new tab)510(k)2025-06-10
Viz Subdural+
K232363 (opens in new tab)510(k)2024-02-05
Viz HDS, Viz Volume Plus, Viz ICH+
DEN230003 (opens in new tab)De Novo2023-08-03
Viz HCM
K223443 (opens in new tab)510(k)2023-03-17
Viz AAA
K223042 (opens in new tab)510(k)2022-10-21
Viz LVO (ContaCT)
Show 7 more
K221100 (opens in new tab)510(k)2022-08-29
Viz RV/LV
K220439 (opens in new tab)510(k)2022-07-25
Viz SDH
K213319 (opens in new tab)510(k)2022-02-18
Viz ANEURYSM
K210209 (opens in new tab)510(k)2021-03-23
Viz ICH
K193658 (opens in new tab)510(k)2020-03-18
Viz ICH
K180161 (opens in new tab)510(k)2018-04-20
Viz CTP
DEN170073 (opens in new tab)De Novo2018-02-13
ContaCT
Peer-reviewed
5 PubMed records name Viz.ai.
- Automated Emergent Large Vessel Occlusion Detection Using Viz.ai Software and Its Impact on Stroke Workflow Metrics and Patient Outcomes in Stroke Centers: A Systematic Review and Meta-analysis. (opens in new tab)
- Revolutionizing Intracranial Hemorrhage Diagnosis: A Retrospective Analytical Study of Viz.ai ICH for Enhanced Diagnostic Accuracy. (opens in new tab)
- Real-world evaluation of the accuracy of the Viz.AI automated intracranial hemorrhage volume calculation tool. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Infervision | Viz.ai |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | 2016 |
| HQ | n/a | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.